# BGB-11417-101 (sonrotoclax): what clinicians are saying

> 133 statements from 27 sources (2 podcasts, 18 videos, 7 posts), 68 of them from 6 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026.

## Report

- Trial: A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
- NCT ID: NCT04277637
- Registry: https://clinicaltrials.gov/study/NCT04277637
- Sponsor: BeOne Medicines
- Phase: Phase 1
- Status: Active, not recruiting
- Drugs tested: sonrotoclax; sonrotoclax plus zanubrutinib; sonrotoclax plus zanubrutinib plus obinutuzumab
- Indication: mature B-cell malignancies
- Version: v1.0.0, edition 1
- Accepted: 2026-11-20 UTC
- Last checked: 2026-11-20 UTC
- Release hash: af919b7af379d3edb63faa112dd40a804e2eb49abf832564df5a6e5bb11a4e88

## Counts

- Commentary sources screened: 55
- Sources cited by verified statements: 27
- Verified statements: 133
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 68
- Findings: 13
- Named people in screened sources (unnamed speakers and accounts not counted): 11
- Speakers cited: 11
- Cited speakers with a verified identity: 9
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 6
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 6
- By role and specialty (the abstract's specialty counts):
  - 3 physician, specialty not confirmed
  - 2 physician, Medical oncology
  - 1 physician, Hematology
- Organisational or shared accounts (not counted as people): 1

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A hematologist described in the sources as reporting their own results reads BGB-11417-101 favorably for its MRD clearance, but remains uncertain about PFS translation. A speaker described as presenting and authoring the results envisages displacing ibrutinib–venetoclax on tolerability grounds; another speaker described as presenting the trial emphasizes response depth. These predictions lack a direct comparison between combinations. Longer follow-up and randomized confirmation are still awaited.

## Question clinicians left open

What do clinicians say they need to see from longer follow-up of sonrotoclax plus zanubrutinib in CLL to determine whether undetectable MRD translates into prolonged PFS?

From finding F1 (11 statements from 2 speakers in 4 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. CLL MRD depth: what speakers highlight without settling its clinical meaning
  - 11 statements from 2 speakers in 4 sources, all podcasts or videos.
  - 2 of the 2 named speakers in this finding hold this view; 2 of them hold its caveat, “without settling its clinical meaning”.
  - 1 of the report's 6 cited clinicians.
- F2. CLL doublets: why some speakers foresee possible replacement of ibrutinib–venetoclax
  - 18 statements from 4 speakers in 9 sources, all podcasts or videos.
  - 2 of the 4 named speakers in this finding hold this view.
  - 2 of the report's 6 cited clinicians.
- F3. CLL: a speaker favors finite therapy but retains a continuous BTKi option
  - 6 statements from 1 speaker in 1 source, a podcast or video.
  - The one named speaker in this finding holds this view; 1 of them holds its caveat, “retain a continuous BTKi option”.
  - No named clinician · accounts and unnamed speakers.
- F4. CLL doublet: how most speakers weigh tolerability against neutropenia and infections
  - 15 statements from 3 speakers in 9 sources, 7 of them podcasts or videos.
  - 2 of the 3 named speakers in this finding hold this view.
  - 2 of the report's 6 cited clinicians.
- F5. 320-mg sonrotoclax: why a speaker sees an efficacy–tolerability balance, not an MTD
  - 5 statements from 2 speakers in 4 sources, all podcasts or videos.
  - 1 of the 2 named speakers in this finding holds this view; 2 of the 2 hold its caveat, “not an MTD”.
  - 1 of the report's 6 cited clinicians.
- F6. Ramp-up: a speaker eyes shortening after study; a clinician values outpatient use
  - 9 statements from 3 speakers in 7 sources, all podcasts or videos.
  - 1 of the 3 named speakers in this finding holds this view; 1 of the 3 holds its caveat, “a clinician values outpatient use”.
  - 1 of the report's 6 cited clinicians.
- F7. R/R CLL: a clinician highlights MRD depth but leaves time off treatment unspecified
  - 16 statements from 1 speaker in 2 sources, all podcasts or videos.
  - The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “leave time off treatment unspecified”.
  - 1 of the report's 6 cited clinicians.
- F8. First-line CLL: what speakers highlight in response rates and uMRD
  - 16 statements from 3 speakers in 5 sources, 2 of them podcasts or videos.
  - 3 of the 3 named speakers in this finding hold this view.
  - 1 of the report's 6 cited clinicians.
- F9. Sonrotoclax–obinutuzumab: a clinician sees MRD-led stops; one awaits an RCT
  - 8 statements from 2 speakers in 2 sources, 1 of them a podcast or video.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of the 2 holds its caveat, “one awaits an RCT”.
  - 2 of the report's 6 cited clinicians.
- F10. CLL triplet: what a clinician highlights in early off-treatment remission
  - 12 statements from 1 speaker in 1 source, a podcast or video.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 6 cited clinicians.
- F11. Sonrotoclax in MCL: where speakers split on how far early findings go
  - 6 statements from 2 speakers in 4 sources, 2 of them podcasts or videos.
  - 2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other.
  - 1 of the report's 6 cited clinicians.
- F12. Sonrotoclax in WM: why most speakers see phase 1 as grounds for further study
  - 9 statements from 3 speakers in 3 sources, 2 of them podcasts or videos.
  - 2 of the 3 named speakers in this finding hold this view.
  - 2 of the report's 6 cited clinicians.
- F13. Phase 1 sonrotoclax: a clinician tempers DLBCL hopes but favors CLL combination study
  - 11 statements from 2 speakers in 4 sources, all podcasts or videos.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “favor CLL combination study”.
  - 1 of the report's 6 cited clinicians.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 11 | 6 | 4 | 2 | 2 |
| F2 | 18 | 12 | 9 | 4 | 3 |
| F3 | 6 | 3 | 1 | 1 | 3 |
| F4 | 15 | 12 | 9 | 3 | 3 |
| F5 | 5 | 5 | 4 | 2 | 2 |
| F6 | 9 | 9 | 7 | 3 | 3 |
| F7 | 16 | 4 | 2 | 1 | 3 |
| F8 | 16 | 8 | 5 | 3 | 2 |
| F9 | 8 | 2 | 2 | 2 | 3 |
| F10 | 12 | 3 | 1 | 1 | 4 |
| F11 | 6 | 4 | 4 | 2 | 3 |
| F12 | 9 | 3 | 3 | 3 | 3 |
| F13 | 11 | 6 | 4 | 2 | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 7 | 2 | 0 | 1 | 1 | 11 | 2 | 4 podcasts and video |
| F2 | 6 | 1 | 1 | 9 | 1 | 18 | 2 | 9 podcasts and video |
| F3 | 3 | 2 | 0 | 1 | 0 | 7 | 0 | 1 podcast or video |
| F4 | 7 | 0 | 0 | 4 | 4 | 17 | 2 | 2 posts and articles, 7 podcasts and video |
| F5 | 2 | 0 | 0 | 0 | 3 | 5 | 0 | 4 podcasts and video |
| F6 | 4 | 0 | 0 | 3 | 2 | 10 | 0 | 7 podcasts and video |
| F7 | 9 | 0 | 0 | 2 | 5 | 18 | 0 | 2 podcasts and video |
| F8 | 12 | 0 | 0 | 0 | 4 | 19 | 3 | 3 posts and articles, 2 podcasts and video |
| F9 | 3 | 1 | 1 | 1 | 2 | 8 | 0 | 1 post or article, 1 podcast or video |
| F10 | 4 | 0 | 0 | 1 | 7 | 16 | 0 | 1 podcast or video |
| F11 | 4 | 0 | 0 | 1 | 1 | 6 | 0 | 2 posts and articles, 2 podcasts and video |
| F12 | 6 | 0 | 1 | 0 | 2 | 9 | 0 | 1 post or article, 2 podcasts and video |
| F13 | 7 | 0 | 0 | 1 | 3 | 16 | 1 | 4 podcasts and video |

### Trial dimensions

- Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs): F4 (11 shared claims), F6 (1 shared claims), F7 (3 shared claims), F9 (4 shared claims), F10 (2 shared claims), F12 (1 shared claims), F13 (2 shared claims)
- Primary endpoint: Number of Participants Experiencing Serious Adverse Events (SAEs): no finding draws on it directly
- Primary endpoint: Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax: F4 (1 shared claims), F9 (3 shared claims), F10 (1 shared claims), F12 (1 shared claims)
- Primary endpoint: Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax: F5 (3 shared claims), F7 (1 shared claims)
- Primary endpoint: Part 1, Part 3, Part 5: RP2D of Sonrotoclax: F4 (1 shared claims), F5 (3 shared claims), F7 (1 shared claims), F10 (1 shared claims), F13 (1 shared claims)
- Primary endpoint: Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events: F4 (3 shared claims), F6 (5 shared claims), F7 (1 shared claims), F8 (2 shared claims), F9 (3 shared claims), F10 (2 shared claims), F12 (1 shared claims), F13 (1 shared claims)
- Primary endpoint: Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs: F5 (2 shared claims)
- Secondary endpoints: F2 (2 shared claims), F6 (3 shared claims), F10 (1 shared claims)
- Population and setting: F2 (1 shared claims), F3 (2 shared claims), F4 (2 shared claims), F6 (1 shared claims), F7 (3 shared claims), F8 (1 shared claims), F10 (3 shared claims), F11 (1 shared claims), F12 (1 shared claims), F13 (1 shared claims)
- The comparison: F1 (2 shared claims), F2 (8 shared claims), F3 (2 shared claims), F7 (1 shared claims), F8 (3 shared claims), F9 (3 shared claims), F10 (3 shared claims), F12 (1 shared claims), F13 (2 shared claims)
- Safety and tolerability: F1 (1 shared claims), F2 (2 shared claims), F4 (12 shared claims), F6 (4 shared claims), F7 (4 shared claims), F8 (2 shared claims), F9 (2 shared claims), F10 (3 shared claims), F11 (2 shared claims), F12 (1 shared claims), F13 (3 shared claims)
- Design and conduct: F1 (2 shared claims), F3 (1 shared claims), F5 (3 shared claims), F6 (2 shared claims), F7 (3 shared claims), F9 (2 shared claims), F10 (6 shared claims), F13 (2 shared claims)

## Abbreviations

- AE: adverse event
- DLT: dose-limiting toxicity
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- MRD: measurable residual disease
- MTD: maximum tolerated dose
- NPI: National Provider Identifier, the US registry number for clinicians
- PFS: progression-free survival
- RCT: randomized controlled trial
- RP2D: recommended phase 2 dose
- SAE: serious adverse event

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 13 | Titles free |
| Detailed analysis | 14 sections | Paid |
| Verified statements with short source quotes and links | 133 | Paid |
| Who said each statement: the cited speakers | 11 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 6 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 9 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 17 | Free |
| Sources with links | 27 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 6 of the 11 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

16 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) | discussed | 19 | 12 |
| Primary endpoint: Number of Participants Experiencing Serious Adverse Events (SAEs) | no commentary found | 0 | 0 |
| Primary endpoint: Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax | discussed | 6 | 5 |
| Primary endpoint: Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax | discussed | 3 | 3 |
| Primary endpoint: Part 1, Part 3, Part 5: RP2D of Sonrotoclax | discussed | 5 | 5 |
| Primary endpoint: Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events | discussed | 15 | 11 |
| Primary endpoint: Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs | discussed | 2 | 2 |
| Secondary endpoints | discussed | 4 | 4 |
| Population and setting | discussed | 16 | 10 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 26 | 16 |
| Safety and tolerability | discussed | 30 | 16 |
| Design and conduct | discussed | 19 | 8 |
| How speakers interpret MRD depth, response and durability | discussed | 36 | 16 |
| Finite therapy, continuous BTK inhibition and patient burden | discussed | 14 | 5 |
| Pharmacologic differentiation, resistance hypotheses and escalation opportunities | discussed | 21 | 14 |
| Histology-specific activity and reasons for further development | discussed | 19 | 10 |
| Research enrollment, validation needs and strength of endorsement | discussed | 25 | 21 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 119 statements · 89%** | | | |
| YouTube | 94 | 17 | 18 |
| X videos | 1 | 1 | 1 |
| Podcasts | 24 | 2 | 2 |
| **Posts · 14 statements · 11%** | | | |
| X threads | 9 | 6 | 31 |
| Bluesky threads | 5 | 1 | 3 |

- Screened window: 2021-04-14 to 2026-11-11
- Cited window: 2021-06-11 to 2026-07-21
- Retrieved: 2026-11-19

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
- Registry: NCT04277637 (https://clinicaltrials.gov/study/NCT04277637)
- Study IDs: BGB-11417-101 · 2024-515592-35-00 · 2020-004641-37
- Sponsor: BeOne Medicines
- Design: Phase 1 · interventional, non randomized, parallel, phase1
- Status: Active, not recruiting
- Enrollment: 437 (actual)
- Start: 2020-03-24 (actual)
- Primary completion: 2027-05-31 (estimated)
- Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) (Up to 30 days after the last dose of study drug, an average of 18 months)
- Primary endpoint: Number of Participants Experiencing Serious Adverse Events (SAEs) (Up to 30 days after the last dose of study drug, an average of 18 months)
- Primary endpoint: Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax (Up to 30 days after the last dose of study drug, an average of 18 months)
- Primary endpoint: Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax (Up to approximately 2 months)
- Primary endpoint: Part 1, Part 3, Part 5: RP2D of Sonrotoclax (Day 1 to last dose of study drug, an average of 18 months)
- Primary endpoint: Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events (Up to 30 days after the last dose of study drug, an average of 18 months)
- Primary endpoint: Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs (Up to approximately 2 months)
- Intervention: Sonrotoclax (drug)
- Intervention: Zanubrutinib (drug)
- Intervention: Obinutuzumab (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- 1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.
- Not yet captured in this edition: a view on the efficacy and tolerability of frontline sonrotoclax plus zanubrutinib in CLL; a remark on early-phase safety and activity in Waldenström macroglobulinemia, including prior BTK inhibitor exposure; a remark on speaker attribution and the relayed nature of first-line sonrotoclax–zanubrutinib commentary; a view on fixed-duration frontline CLL treatment alternatives and their long-term efficacy and safety considerations.
- 2 passages in 2 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 47 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 21 sources about other trials or topics are not included.
- The sources reviewed for this edition are selected public discussions rather than a representative survey of HCP practice or opinion.
- Several speakers are described by their sources as presenting, authoring or reporting the trial. Those descriptions are attributed source information, not independent confirmation of involvement or an external endorsement.
- Repeated posts, reposts, interviews and reused excerpts should not be counted as independent HCP endorsements.
- Some remarks remain unnamed even when a source title, introduction or participant list names a possible speaker. Those remarks cannot establish ownership of a named view.
- No protocol or exact-trial results publication was available among the sources reviewed, limiting checks of cohort definitions, denominators and event attribution.
- Different updates use different settings, dose cohorts, MRD thresholds, evaluable populations and follow-up. Their percentages and no-event statements should not be pooled.
- Unclear deletion labels and inconsistent recalled timing are left unresolved. They are not corrected to a presumed clinical meaning.
- No separate assessment or count of serious adverse events was found in the commentary presented here; high-grade toxicity statements cannot substitute for that endpoint.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-20 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-20 UTC. No changes.

## Offer

- Size: Focused · 133 verified statements · 68 from 6 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (9 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/bgb-11417-101-nct04277637
- Agents: POST https://www.erudio.com/api/orders with {"report": "bgb-11417-101-nct04277637", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=bgb-11417-101-nct04277637

## Cite

Erudio Health. BGB-11417-101 (NCT04277637): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/bgb-11417-101-nct04277637

## Questions

### How much does the BGB-11417-101 report cost?

One edition costs $750 (Focused · 133 verified statements · 68 from 6 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the BGB-11417-101 report cover?

133 statements from 27 sources (2 podcasts, 18 videos, 7 posts), 68 of them from 6 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the BGB-11417-101 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "bgb-11417-101-nct04277637" }) previews it and create_order({ "report": "bgb-11417-101-nct04277637", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the BGB-11417-101 report?

Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/bgb-11417-101-nct04277637.json
- Markdown: https://www.erudio.com/reports/bgb-11417-101-nct04277637.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/bgb-11417-101-nct04277637/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "bgb-11417-101-nct04277637"}`
